BioNTech stock is a "Strong Buy", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read ...

A rapid, two-step immune reaction may underlie rare cases of heart inflammation seen after Covid mRNA vaccination, Stanford ...

BioNTech's latest narrative update reflects a slightly higher fair value estimate of about $138, tempered by a modestly increased discount rate of roughly 6.72%, as analysts balance confidence in the ...

BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative ...

Pfizer's COVID-19 vaccine has become the first in the U.S. to receive full approval from the FDA for people ages 16 and up.

BioNTech SE (NASDAQ:BNTX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Clear ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus ...

BioNTech SE ( ($BNTX) ) has issued an announcement. On December 9, 2025, BioNTech SE and Bristol Myers Squibb announced interim results from a ...

Bank of America upgrades Bristol Myers to Buy, lifting its price target to $61 on pipeline catalysts, valuation support, and ...

Five years after she took the First COVID-19 shot in the US, Sandra Lindsay reflects on hope and how it's challenging to ...

It may feel like you are surrounded by sniffles and coughs, but flu season activity is still low in many parts of the U.S.